LONDON--(BUSINESS WIRE)--The global castration-resistant prostate cancer (CRPC) treatment market is expected to grow at a CAGR of more than 9% during the forecast period, according to Technavio’s ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer. This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD ...

Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. Epidermal growth factor receptor (EGFR) targeted therapy in ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

This week, the FDA approved radium-223 injection for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. It is the first FDA-approved alpha particle-emitting ...